[Use of calcium inhibitors excluding cardiac pathology and arterial hypertension].
Many studies have been done to try to define new therapeutic uses for calcium antagonists, in diseases in which calcium plays a role. Positive results have been obtained in the prevention of acute attacks of idiopathic Raynaud's disease and migraine, and in effort-induced asthma. Some activity could be demonstrated in selected groups of patients with pulmonary hypertension, manic-depressive illness, untractable epilepsy, various functional gynecological or digestive disorders, and in drug-induced nephrotoxicity. A possible effect on the prevention of resistance to anti-cancer drugs could be of major interest. Their antiplatelet effect, and their possible effect against atherosclerosis, which remains to be confirmed, their lack of side-effects in asthmatics and of interference with glucose regulation increase their usefulness in patients with hypertension or ischemic heart disease, especially when other diseases are present.
Hugues
F C
FC
Le Jeunne
C
C
D000818:Animals; D000970:Antineoplastic Agents; D001249:Asthma / Q000188:drug therapy*; D001927:Brain Diseases / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008881:Migraine Disorders / Q000188:drug therapy*; D011928:Raynaud Disease / Q000188:drug therapy*
D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers
Utilisation des inhibiteurs des transferts calciques en dehors de la pathologie cardiaque et de l'hypertension artérielle.